Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to keep leukemia at bay after first treatment

NCT ID NCT07509151

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 7 times

Summary

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive surovatamig as a shot under the skin or be watched without extra treatment. The study focuses on patients whose cancer has a genetic marker called unmutated IGHV, which tends to be more aggressive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Surovatamig (also known as TNB-486, AZD0486) - a drug given as a shot under the skin
What this could lead to
If successful, this could provide a new option to keep CLL/SLL in check longer after initial treatment, potentially delaying relapse.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may cause side effects or not improve outcomes compared to observation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV. * Treatment received and response at the end of 1L (first-line) finite therapy. * Participants with SLL (except those in CR in Phase III part) must have measurable disease (nodal or extranodal) with at least one measurable target lesion. * ECOG performance status of 0 to 2. * Adequate haematologic, liver, renal and cardiac function. * Female participants: must be either women not of childbearing potential or must use a highly effective form of contraception. * Male participants who intend to be sexually active with females of childbearing potential must agree to use barrier contraception (eg, condoms). Exclusion Criteria: * Suspected or confirmed transformation of CLL/SLL to a more aggressive form of lymphoma (ie, Richter's transformation, prolymphocytic leukaemia, or DLBCL). * Evidence of active or history of Central Nervous System (CNS) involvement by CLL/SLL. * History of or ongoing confirmed progressive multifocal leukoencephalopathy. * Participants who have any concurrent or history of malignancy. * Participants with: * Active or uncontrolled infection (including Epstein-Barr virus-EBV) requiring systemic therapy. * Participants with known history of Heamophagocytic lymphohistiocytosis (HLH). * Human Immunodeficiency Virus (HIV) infection, or participants with chronic or active infection with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). * Major cardiac abnormalities. * Prior CLL/SLL-specific therapies. * Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition or prior allogeneic stem cell or solid organ transplant. * Major surgical procedure. * Known hypersensitivity to surovatamig or any of the excipients of the product.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukaemia or small lymphocytic lymphoma with unmutated ighv are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia Leukemia, B-Cell lymphoma pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukaemia or small lymphocytic lymphoma with unmutated ighv

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    44 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    La Jolla, California, 92093, United States

  • Research Site

    NOT_YET_RECRUITING

    Denver, Colorado, 80218, United States

  • Research Site

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06510, United States

  • Research Site

    NOT_YET_RECRUITING

    Chicago, Illinois, 60637, United States

  • Research Site

    NOT_YET_RECRUITING

    Kansas City, Kansas, 66210, United States

  • Research Site

    NOT_YET_RECRUITING

    Louisville, Kentucky, 40207, United States

  • Research Site

    NOT_YET_RECRUITING

    Bethesda, Maryland, 20817, United States

  • Research Site

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

  • Research Site

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    NOT_YET_RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Research Site

    NOT_YET_RECRUITING

    Rochester, New York, 14642, United States

  • Research Site

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Research Site

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    NOT_YET_RECRUITING

    Adelaide, 5000, Australia

  • Research Site

    NOT_YET_RECRUITING

    Fitzroy, 3065, Australia

  • Research Site

    RECRUITING

    Heidelberg, 3084, Australia

  • Research Site

    RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    NOT_YET_RECRUITING

    Perth, 6847, Australia

  • Research Site

    NOT_YET_RECRUITING

    Rockingham, 6168, Australia

  • Research Site

    RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    SUSPENDED

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Research Site

    NOT_YET_RECRUITING

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Research Site

    NOT_YET_RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M5G 2L7, Canada

  • Research Site

    SUSPENDED

    Montreal, Quebec, H2L 4M1, Canada

  • Research Site

    NOT_YET_RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Research Site

    SUSPENDED

    Québec, Quebec, G1J 1Z4, Canada

  • Research Site

    RECRUITING

    Adapazarı, 54100, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Antalya, 07025, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Istanbul, 34098, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Istanbul, 34517, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Istanbul, 34899, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Kocaeli, 41380, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Mezitli, 33200, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Hampshire, SO16 6YD, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • Research Site

    RECRUITING

    London, NW1 2BU, United Kingdom

  • Research Site

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Research Site

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • Research Site

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Research Site

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.